Healthcare provider profile · identity verified

John Christopher Mcfadden, MD

Family Practice · HIGH POINT, NC · NPI 1770503930

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	328	144
Amlodipine Besylate	Amlodipine Besylate	231	94
Metoprolol Succinate	Metoprolol Succinate	149	68
Omeprazole	Omeprazole	147	62
Levothyroxine Sodium	Levothyroxine Sodium	145	60
Lisinopril	Lisinopril	140	55
Fluticasone Propionate	Fluticasone Propionate	125	49
Pantoprazole Sodium	Pantoprazole Sodium	118	45
Losartan Potassium	Losartan Potassium	116	55
Gabapentin	Gabapentin	113	42
Montelukast Sodium	Montelukast Sodium	108	48
Pravastatin Sodium	Pravastatin Sodium	99	42
Rosuvastatin Calcium	Rosuvastatin Calcium	98	42
Duloxetine Hcl	Duloxetine Hcl	95	36
Simvastatin	Simvastatin	86	36
Eliquis	Apixaban	84	16
Sertraline Hcl	Sertraline Hcl	72	25
Allopurinol	Allopurinol	64	27
Azelastine Hcl	Azelastine Hcl	63	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	62	23
Metformin Hcl	Metformin Hcl	62	28
Bupropion Xl	Bupropion Hcl	57	21
Glipizide Er	Glipizide	53	27
Hydrochlorothiazide	Hydrochlorothiazide	53	27
Furosemide	Furosemide	52	28
Carvedilol	Carvedilol	50	21
Esomeprazole Magnesium	Esomeprazole Magnesium	49	21
Citalopram Hbr	Citalopram Hydrobromide	48	19
Escitalopram Oxalate	Escitalopram Oxalate	45	23
Venlafaxine Hcl Er	Venlafaxine Hcl	45	12
Albuterol Sulfate Hfa	Albuterol Sulfate	42	15
Ozempic	Semaglutide	42	15
Potassium Chloride	Potassium Chloride	42	17
Clopidogrel	Clopidogrel Bisulfate	40	16
Celecoxib	Celecoxib	39	suppressed
Alendronate Sodium	Alendronate Sodium	37	11
Metoprolol Tartrate	Metoprolol Tartrate	37	15
Tamsulosin Hcl	Tamsulosin Hcl	36	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	14
Ezetimibe	Ezetimibe	35	17
Famotidine	Famotidine	34	11
Meloxicam	Meloxicam	33	12
Metformin Hcl Er	Metformin Hcl	32	13
Alprazolam	Alprazolam	31	20
Tizanidine Hcl	Tizanidine Hcl	30	17
Trazodone Hcl	Trazodone Hcl	30	13
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Glimepiride	Glimepiride	26	11
Jardiance	Empagliflozin	25	suppressed
Mupirocin	Mupirocin	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	14
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	21	suppressed
Labetalol Hcl	Labetalol Hcl	21	suppressed
Irbesartan	Irbesartan	20	suppressed
Atenolol	Atenolol	18	suppressed
Fluconazole	Fluconazole	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Acyclovir	Acyclovir	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	14
Januvia	Sitagliptin Phosphate	16	suppressed
Lactulose	Lactulose	16	suppressed
Prednisone	Prednisone	16	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Valsartan	Valsartan	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Ramipril	Ramipril	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error